David Venables
Amministratore Delegato presso Synpromics Ltd.
Profilo
David C.
Venables is currently the Chief Executive Officer at Synpromics Ltd.
and the Chief Executive Officer & Director at Laverock Therapeutics Ltd.
Previously, he held positions such as Chief Executive Officer, Director & MD at Anatara Lifesciences Ltd.
from 2014 to 2015, Non-Executive Director at Ark Therapeutics Group Plc from 2012 to 2015, Operations Director at Q-One Biotech Ltd., Head-Process Development at Medeva Plc, and Chief Operating Officer at Intercell USA, Inc. He obtained his doctorate degree from the University of Surrey in 1993.
Posizioni attive di David Venables
| Società | Posizione | Inizio |
|---|---|---|
Synpromics Ltd.
 Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Amministratore Delegato | - |
Laverock Therapeutics Ltd.
 Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Amministratore Delegato | 01/08/2021 |
Precedenti posizioni note di David Venables
| Società | Posizione | Fine |
|---|---|---|
Ark Therapeutics Group Plc
 Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 27/02/2015 |
| ANATARA LIFESCIENCES LTD | Amministratore Delegato | 24/02/2015 |
| Q-One Biotech Ltd. | Corporate Officer/Principal | - |
| Medeva Plc | Corporate Officer/Principal | - |
| IOMAI CORPORATION | Direttore operativo | - |
Formazione di David Venables
| University of Surrey | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ANATARA LIFESCIENCES LTD | Health Technology |
| Aziende private | 6 |
|---|---|
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Commercial Services |
Intercell USA, Inc.
 Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
| Medeva Plc | Health Technology |
| Q-One Biotech Ltd. | Health Technology |
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Process Industries |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Health Technology |
- Borsa valori
- Insiders
- David Venables
